1. |
Selective COX-2 inhibitors for acute gout? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
EU pharma law undergoes major reforms |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Remifentanil cost savingvsfentanyl in CABG surgery? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Emtricitabine shows superiority to stavudine in HIV infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 7-8
Ed Susman,
Preview
|
|
摘要:
Emtricitabine [FTC; 'Coviracil'] is more effective and better tolerated than stavudine when the nucleoside reverse transcriptase inhibitors were used as part of a 3-drug combination in the treatment of antiretroviral-naïve patients with HIV infections, according to results of a pivotal phase III study presented at the 42nd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [San Diego, US; September 2002].'In this study, once daily emtricitabine with didanosine and efavirenz was statistically superior to stavudine, didanosine and efavirenz in efficacy, safety and tolerability',said presenter Dr Michael Saag from the University of Alabama at Birmingham, US.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News from ACR meeting ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
NASHA promising in facial soft-tissue augmentation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1363,
2002,
Page 11-12
Andrew Fitton,
Preview
|
|
摘要:
Injectable soft-tissue filler substances play an important role in the cosmetic treatment of the aging face and the correction of soft-tissue defects. These viscoelastic substances provide volume expansion within the dermis, thereby smoothing out overlying facial wrinkles and folds and enhancing facial contours. Their ease of use and the minimal discomfort associated with the intradermal injection procedure make injectable fillers well suited for outpatient use. Ideally, a filler material should be biocompatible, nontoxic, nonimmunogenic, nonmigratory, and nonresorbable. Several biomaterials have been developed, such as bovine collagen, autologous and allogeneic human collagen, autologous fat and fibroblasts, and hyaluronic acid. However, currently available biomaterials have limitations; although they are largely biocompatible, reabsorption and lack of permanency of cosmetic effect are major drawbacks. A stabilised hyaluronic acid gel of nonanimal origin shows improved durability of effect in facial soft-tissue augmentation compared with these products, according to data presented at a Q-Med (Sweden)-sponsored workshop at the 11th Congress of the European Academy of Dermatology and Venereology (EADV) [Prague, Czech Republic; October 2002].1
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|